Statera Biopharma, Inc.
STAB · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.03 | 0.65 | 0.25 |
| FCF Yield | -35.14% | -3.96% | -0.19% | -8.15% |
| EV / EBITDA | 2.44 | -12.58 | -55.20 | -11.03 |
| Quality | ||||
| ROIC | -1,141.10% | 694.97% | -913.99% | -132.50% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.28 | 1.20 | 0.07 | 1.24 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -457.30% | -2,018.31% | 94.79% | 30.22% |
| Safety | ||||
| Net Debt / EBITDA | 0.37 | -0.14 | -0.76 | 0.75 |
| Interest Coverage | 0.00 | -9.29 | -22.65 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,963.69 | 0.00 | 0.00 | 0.00 |